Skip to main content

Advertisement

Table 1 Patient data by gender

From: Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry

  Females Males All patients
Total cohort (N) 587 628 1215
Missing date of birth (n) 9 12 21
Missing date of diagnosis (n) 5 7 12
Median age at diagnosis in years [range] 50.5 [5.4-92.2] 52.6 [10.0-90.0] 51.7 [5.4-92.2]
Median follow-up time in years [range] 4.5 [0-39.5] 5.8 [0-30.6] 5.2 [0-39.5]
Death events (n) 117 195 312
Total survival cohort (n) 578 617 1195
Primary tumor location (n) 523 565 1088
Tumor site, survival (n) 519 556 1075
Disease status at diagnosis (n) 587 628 1215
Disease status, survival analyses (n) 578 617 1195
Confidence in no metastatic/advanced disease report (see methods for description)    
   High confidence 114 100 214
   Intermediate confidence 102 96 198
   Low confidence 5 12 17
   Report of metastatic/advanced disease 366 420 786
Mutation data (n) 164 161 325
Mutation, survival (n) 164 160 324
Continent of birth (n)    
   N. America 468 489 957
   Europe 69 71 140
   Asia 30 43 73
   Oceania 7 9 16
   S. America 6 10 16
   Africa 6 3 9
   Unknown 1 3 4
  1. Patients missing a date of birth were not included in analyses based on age at diagnosis (n = 21). Follow-up was calculated from date of diagnosis until date of last update (or endpoint) in years. Survival cohort and sub-groups includes those patients for which overall survival could be estimated. Continents of birth were grouped post hoc from reported country of birth